KZIA stock news · Kazia Therapeutics
Get alerts for KZIA
Follow Kazia Therapeutics (KZIA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for KZIAFree on the App Store and Google Play, or on the web.
Kazia Therapeutics said two studies about its drug paxalisib will be shown at the 2026 San Antonio Breast Cancer Symposium.
NeutralKazia had 2 research abstracts accepted for poster presentation at the 2026 San Antonio Breast Cancer Symposium. The story gives no study findings, so it does not change what is known about the company's prospects.
Kazia Therapeutics will join a discussion at the Guggenheim Healthcare Innovation Conference on November 9 to 11.
NeutralKazia will join a healthcare conference and offer a public webcast. The appearance gives people access to its leaders but reports no new business change, so Kazia's outlook is unchanged.
Leerink Partners starts following Kazia Therapeutics, saying it could do well with a $30 price goal.
Good for KZIALeerink started coverage of Kazia with an Outperform rating and a $30 target, giving KZIA a favorable new outside assessment, though no company results changed.